Immunovia AB (publ)
STO:IMMNOV

Watchlist Manager
Immunovia AB (publ) Logo
Immunovia AB (publ)
STO:IMMNOV
Watchlist
Price: 0.214 SEK 5.16%
Market Cap: kr144m

Wall Street
Price Targets

IMMNOV Price Targets Summary
Immunovia AB (publ)

Wall Street analysts forecast IMMNOV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMMNOV is 0.745 SEK with a low forecast of 0.737 SEK and a high forecast of 0.767 SEK.

Lowest
Price Target
0.737 SEK
245% Upside
Average
Price Target
0.745 SEK
248% Upside
Highest
Price Target
0.767 SEK
258% Upside
Immunovia AB (publ) Competitors:
Price Targets
UMBF
UMB Financial Corp
15% Upside

Revenue
Forecast

10% / Year
Past Growth
182% / Year
Estimated Growth
Estimates Accuracy
-99%
Average Miss
10% / Year
Past Growth
182% / Year
Estimated Growth
Estimates Accuracy
-99%
Average Miss

For the last 10 years the compound annual growth rate for Immunovia AB (publ)'s revenue is 10%. The projected CAGR for the next 4 years is 182%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
26%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
26%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-91%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-91%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IMMNOV's stock price target?
Price Target
0.745 SEK

According to Wall Street analysts, the average 1-year price target for IMMNOV is 0.745 SEK with a low forecast of 0.737 SEK and a high forecast of 0.767 SEK.

What is Immunovia AB (publ)'s Revenue forecast?
Projected CAGR
182%

For the last 10 years the compound annual growth rate for Immunovia AB (publ)'s revenue is 10%. The projected CAGR for the next 4 years is 182%.

Back to Top